Señales en vivo de 688687.SS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 03:00):

Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China...

Stats
Volumen de hoy	3.89M
Volumen promedio	6.08M
Capitalización de mercado	5.29B
EPS	CNY0.130 ( 2024-04-30 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	44.54
ATR14	CNY0.0550 (0.17%)

Volumen Correlación

Largo: -0.23 (neutral)

Corto: 0.85 (strong)

Signal:(50.943) Same movement expected

Beijing Kawin Technology Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Beijing Kawin Technology Correlación - Moneda/Commodity

-0.07
( neutral )

-0.01
( neutral )

0.00
( neutral )

-0.56
( weak negative )

0.17
( neutral )

0.59
( weak )

Beijing Kawin Technology Finanzas

Annual	2023
Ingresos:	CNY1.41B
Beneficio Bruto:	CNY1.18B (83.55 %)
EPS:	CNY0.700

FY	2023
Ingresos:	CNY1.41B
Beneficio Bruto:	CNY1.18B (83.55 %)
EPS:	CNY0.700

FY	2022
Ingresos:	CNY1.16B
Beneficio Bruto:	CNY1.00B (86.60 %)
EPS:	CNY0.500

FY	2021
Ingresos:	CNY1.14B
Beneficio Bruto:	CNY1.00B (87.68 %)
EPS:	CNY0.660

Financial Reports:

No articles found.

Beijing Kawin Technology

Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substancesfermentation and purification, drug productformulation, and analytical methods development; and contract manufacturing services. The company also serves customers in Pakistan, Colombia, Philippines, Vietnam, Russia, Cambodia, and others. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.